Modality
mRNA
MOA
PLK4i
Target
CD47
Pathway
Tau
DravetMDSET
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
Jun 2019
→ Sep 2030
Phase 2Current
NCT08418117
2,407 pts·Dravet
2019-06→TBD·Terminated
NCT07215277
2,689 pts·ET
2023-04→2030-09·Not yet recruiting
5,096 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-044.4y awayPh3 Readout· ET
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Termina…
P2/3
Not yet…
Catalysts
Ph3 Readout
2030-09-04 · 4.4y away
ET
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08418117 | Phase 2/3 | Dravet | Terminated | 2407 | UPDRS |
| NCT07215277 | Phase 2/3 | ET | Not yet recr... | 2689 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Terazumab | Akero | NDA/BLA | CD47 |